Kymera Therapeutics, Inc.

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
36.01 ^USD	+3.03%		-6.13%	+41.44%

May. 16	Transcript : Kymera Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:20 PM
May. 14	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting	CI

Kymera Therapeutics, Inc. Announces Departure of Elaine Caughey as Chief Business Officer

February 27, 2023 at 05:22 pm EST

On February 27, 2023 Kymera Therapeutics, Inc. announced that Elaine Caughey, its Chief Business Officer, will be departing the Company for personal family reasons effective as of April 10, 2023.

Latest news about Kymera Therapeutics, Inc.

Transcript : Kymera Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:20 PM	May. 15
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting	May. 14	CI
Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53	May. 03	MT
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises	May. 02	MT
Transcript : Kymera Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders	May. 02	CI
Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target	Apr. 22	MT
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	Apr. 08	CI
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	Apr. 01	CI
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	Mar. 14	MT
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	Mar. 08	CI
Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating	Mar. 01	MT
Piper Sandler Raises Price Target on Kymera Therapeutics to $56 From $39, Maintains Overweight Rating	Feb. 27	MT
B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating	Feb. 23	MT
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	Feb. 22	MT
Transcript : Kymera Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Wolfe Research Starts Kymera Therapeutics With Peer Perform Rating	Feb. 15	MT
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	Jan. 24	MT
Transcript : Kymera Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Kymera Therapeutics Raises $316.2 Million From Offering, Outlines Cash Runway Guidance	Jan. 09	MT
Morgan Stanley Raises Price Target on Kymera Therapeutics to $33 From $24, Keeps Equalweight Rating	Jan. 08	MT
Kymera Therapeutics Prices $275 Million Common Share Public Offering	Jan. 05	MT

Chart Kymera Therapeutics, Inc.

Duration

Period

More charts

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - TD Cowen Oncology Innovation Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Kymera Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

36.01 USD

Average target price

50.8 USD

Spread / Average Target

+41.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KYMERA THERAPEUTICS, INC.	+41.44%	2.21B
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+47.19%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research